All In Biotech

Drug Trial Radar · NCT00077493

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas

Last checked: Nov 20, 2026Latest source record: Dec 28, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

95

Planned (sponsor's estimate)

Start

Jan 2004

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Cambridge Antibody Technology
First posted
Feb 12, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months, up to 24 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating young patients with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma.

Conditions

  • Leukemia
  • Lymphoma

Interventions

  • BL22 immunotoxinDrug

    BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.

  • antibody-drug conjugate therapyProcedure

    CD22 antibody, RFB4 on day 7

  • immunotoxin therapyProcedure

    tested for immunogenicity to CAT-8015 before each cycle and at end of study.

  • monoclonal antibody therapyProcedure

    administered intravenously over 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. assessment of efficacy, safety, pharmacokinetics, immunogenicity.Time frame: end of study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.